Analysts Set Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Target Price at $17.25

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given a consensus rating of “Hold” by the six research firms that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.25.

AUPH has been the topic of a number of recent research reports. Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $10.00 to $21.00 in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday. Bloom Burton downgraded shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Leerink Partners cut shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and lifted their price objective for the stock from $15.00 to $16.00 in a research note on Wednesday, December 3rd. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. bought a new stake in Aurinia Pharmaceuticals during the third quarter worth about $48,000. State of Alaska Department of Revenue acquired a new position in shares of Aurinia Pharmaceuticals in the 3rd quarter valued at approximately $91,000. USA Financial Formulas acquired a new position in shares of Aurinia Pharmaceuticals in the 3rd quarter valued at approximately $107,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $92,000. Finally, Bailard Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $99,000. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Price Performance

NASDAQ:AUPH opened at $14.53 on Wednesday. The company has a market cap of $1.92 billion, a P/E ratio of 25.95 and a beta of 1.46. The firm’s fifty day moving average price is $15.60 and its two-hundred day moving average price is $13.04. Aurinia Pharmaceuticals has a one year low of $6.55 and a one year high of $16.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.76 and a quick ratio of 5.17.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.07. The business had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. Equities analysts expect that Aurinia Pharmaceuticals will post 0.11 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.